It’s time to confront the pandemic of antibiotic resistance

The article discusses the urgency of the AMR crisis, new data on the burden of AMR, and the need for strong and sustained action from governments, industry and institutional investors. 

"AMR is material to institutional investors, and we need them to play active roles as antibiotics “stewards” across the biotechnology, pharmaceutical, food production, food retail, healthcare, veterinary and insurance sectors," Dame Sally Davies writes. 

"Sixteen partners to the Investor Action on AMR initiative — launched by Access to Medicine Foundation, the FAIRR initiative, the Principles for Responsible Investment network and the UK Department of Health and Social Care — are already using their influence to promote innovation and better risk management. They are also lending their voices to galvanise G7 action."

Click here to read the full article in the Financial times or read more about how we work with investors.